Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

National Institutes of HealthAmount not specifiedDue Oct 20, 2027

Researchers Schools & universities Government / tribal Nonprofits Narrow eligibility

Deadline: Oct 20, 2027
Posted: Nov 4, 2024
Award amount: Amount not specified
Focus areas: Health

Don’t miss this deadline

We’ll email you before Oct 20, 2027 so you have time to apply.

In plain English

This NIH/NINDS award (R61/R33) funds pharmacology and in vivo efficacy studies to advance candidate therapeutics for neurological and neuromuscular disorders toward further translational development. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations rather than individuals. No award amount is specified. The work is narrowly defined preclinical drug-development research.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Health — soonest deadline first.

Also listed under National Institutes of Health and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.